Biotech stands out as a vibrant sector within the small cap market, characterized by its unique firms focused on drug discovery and development. With around 600 public biotech companies, the inefficiencies in this space create lucrative opportunities for investors, as each company navigates its own path through the complexities of FDA approval and financing. The advancements in genomics and technology further enhance the potential for breakthroughs, making this a compelling area for both financial gain and positive societal impact.
